ResearcherAzienda Unità Sanitaria Locale PiacenzaActive in the last 2 years
Chiara Citterio
Matched on ORCID iD 0000-0002-2119-775X; OpenAlex author ID A5081303983. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper
Papers 7
- Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Drug-Drug Interactions and Outcome. Co-author DOI 10.32604/or.2026.076944↗
- Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. Co-author DOI 10.3390/cancers17050747↗
- State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. Last author DOI 10.3390/ijms26062620↗
- Comparing Combination vs Monochemotherapy in Late-Elderly Patients With Advanced Pancreatic Cancer: Insights From a Single-Center Study. First author DOI 10.1177/10732748241304968↗
- FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. First author DOI 10.21873/cdp.10303↗
- Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an attenuated with a full dose in a single cente… Co-author DOI 10.2147/ott.s200754↗
- Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy: a network meta-analysis. Co-author DOI 10.18632/oncotarget.25639↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Elena Orlandi · 7 shared papers, 2018–2026 · strength 1.56
- Paper Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Dr… DOI 10.32604/or.2026.076944↗
- Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
- Paper Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. DOI 10.3390/cancers17050747↗
- Stefano Vecchia · 6 shared papers, 2019–2026 · strength 1.46
- Paper Polypharmacy in Elderly Patients Receiving First-Line Treatment for Pancreatic Adenocarcinoma: Analysis of Potential Dr… DOI 10.32604/or.2026.076944↗
- Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
- Paper Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. DOI 10.3390/cancers17050747↗
- Mario Giuffrida · 2 shared papers, 2025 · strength 0.50
- Paper Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. DOI 10.3390/cancers17050747↗
- Paper State of the Art of Immune Checkpoint Inhibitors in Unresectable Pancreatic Cancer: A Comprehensive Systematic Review. DOI 10.3390/ijms26062620↗
- Luigi Cavanna MD · 3 shared papers, 2018–2024 · strength 0.49
- Paper FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel as First Line Treatment in Pancreatic Cancer: A Real-World Comparison. DOI 10.21873/cdp.10303↗
- Paper Second-line chemotherapy for the treatment of metastatic pancreatic cancer after first-line gemcitabine-based chemother… DOI 10.18632/oncotarget.25639↗
- Paper Modified FOLFIRINOX for unresectable locally advanced/metastatic pancreatic cancer. A real-world comparison of an atten… DOI 10.2147/ott.s200754↗
- Filippo Banchini Banchini · 1 shared paper, 2025 · strength 0.26
- Andrea Romboli · 1 shared paper, 2025 · strength 0.25
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.